TB Alliance grants Fosun Chinese rights to TB regimen

The not-for-profit Global Alliance for TB Drug Development granted Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive rights to develop and commercialize the alliance's PaMZ tuberculosis regimen in China, Taiwan, Hong Kong and Macau. The alliance will receive an undisclosed upfront payment and is eligible for an undisclosed milestone, plus royalties. By year end, the alliance is aiming to start the international Phase III STAND trial to evaluate the regimen for drug-susceptible TB and multidrug-resistant TB (MDR-TB). The Bill & Melinda Gates Foundation will provide "significant" funding for the trial, which is expected to cost $58-$65 million. ...